.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,723,361

« Back to Dashboard

Summary for Patent: 7,723,361

Title:Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide
Abstract:The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Inventor(s): D'Amato; Robert (Lancaster, PA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:11/096,155
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 29th percentile
Forward Citations: 0th percentile
Patent PDF download available with subscription

No matches for this query

Premature patent expiration for: 7,723,361

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
7,723,361 May 25, 2014

International Patent Family for Patent: 7,723,361

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria218865<disabled in preview>
Austria304356<disabled in preview>
Australia6248694<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc